{"id":"hrs-4642-ag","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HRS-4642 inhibits VEGFR, FGFR, and other kinases critical for tumor angiogenesis and proliferation. The combination with AG (likely an additional therapeutic agent) is designed to enhance anti-tumor efficacy through complementary mechanisms in phase 3 development.","oneSentence":"HRS-4642 is an anti-angiogenic tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor vascularization and growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:41.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication under phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT07438106","phase":"PHASE2","title":"A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02","conditions":"Locally Advanced Pancreatic Cancer With KRAS G12D Mutation","enrollment":30},{"nctId":"NCT07240766","phase":"PHASE2","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-15","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07131514","phase":"PHASE2","title":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-25","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT07232875","phase":"PHASE3","title":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12","conditions":"KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting","enrollment":588},{"nctId":"NCT06770452","phase":"PHASE2","title":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-03-25","conditions":"Metastatic Pancreatic Carcinoma","enrollment":32},{"nctId":"NCT06520488","phase":"PHASE1, PHASE2","title":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-08-09","conditions":"Advanced Solid Tumors","enrollment":118},{"nctId":"NCT06587061","phase":"PHASE2","title":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-03","conditions":"Pancreatic Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HRS-4642 + AG","genericName":"HRS-4642 + AG","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HRS-4642 is an anti-angiogenic tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor vascularization and growth. Used for Advanced or metastatic solid tumors (specific indication under phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}